TBPH
insider transactionsTheravance Biopharma, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
CHIEF EXECUTIVE OFFICER
$0
75.0K sh
Own +5%
-
Grant·A
Sawaf Aziz KEY
SVP & CHIEF FINANCIAL OFFICER
$0
37.5K sh
Own +12%
-
Grant·A
SVP, GEN COUNSEL AND SECRETARY
$0
37.5K sh
Own +11%
-
Grant·A
SVP, COMM & MEDICAL AFFAIRS
$0
18.8K sh
Own +8%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 1, 2026 | Winningham Rick E KEY | Grant A | 75.0K | $0 |
| Apr 1, 2026 | Sawaf Aziz KEY | Grant A | 37.5K | $0 |
| Apr 1, 2026 | Grimaud Brett A. | Grant A | 37.5K | $0 |
| Apr 1, 2026 | Unknown | Grant A | 18.8K | $0 |
About TBPH insider trading
This page tracks insider transactions for Theravance Biopharma, Inc. (TBPH) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.